Precision medicine has transformed cancer care over the past 20 years, providing a personalized approach to a disease that previously had been viewed with a one-size-fits-all mentality. Considerable progress in areas like cancer genome research has enabled care teams to determine the best course of pharmacological treatment for patients and revealed opportunities for researchers to develop new targeted therapies. And yet, several critical gaps remain in patient care. Many individuals navigating the cancer journey, whether during active treatment or survivorship, experience fatigue, endure persistent pain, and face clinically significant mood symptoms which can impose an immense emotional toll and significantly impact their quality of life. More innovation is needed to support these patients. Targeted, evidence-based software as prescription medical treatments offer a promising path to precision cancer care alongside pharmacological treatments.

At Click, we are focused on patient-centered care, not just treating the disease, with targeted interventions that impact brain function. We were proud to present results on our first neuromodulatory smartphone-based investigational intervention for breast cancer, the Multimodal Multistable Bias Modification (MMBM™) at the American Society of Clinical Oncology (ASCO) Annual Meeting. The MMBM intervention is designed to address changes in brain circuitry linked to cancer- and cancer-related factors which play a key role in regulating cognitive, emotional, and sensory processes including how patients perceive pain and are able to regulate cancer related distress and mood symptoms. 

In our randomized, controlled pilot trial (NCT06136923) of 81 breast cancer survivors, those in the treatment arm using the MMBM™ app experienced on average a significant improvement compared to a sham control app in fatigue (improvement of 3.4 points, p<0.05), anxiety (improvement by 3.0 points, p<0.05), and depressive symptoms (improvement of 2.8 points, p<0.05) on the PROMIS-29+2 standardized scale after using the app for just seven minutes a day for four weeks. These differences were also clinically significant, where the change was within the 2-6 point minimal clinically important differences threshold. Additionally, only the MMBM app group showed significant improvement across a wide range of pain and pain-related metrics, including pain intensity (average and current), pain interference, pain related distress and physical functioning (all <p=0.05). The study concludes that the MMBM intervention produced clinically meaningful improvements in fatigue, mood, and promising signal across pain symptoms in breast cancer survivors.

These results show how digital interventions like MMBM go beyond traditional app-based support, uniquely addressing factors like fatigue, mood, and pain, that are key drivers of a patient's overall quality of life. This focus is essential in today’s oncology landscape, where quality of life has become a growing priority not only for patients, but clinicians, regulators, and researchers as well. This can be seen in the notable increase of phase III trials measuring quality of life as an endpoint and the growing importance of patient-reported outcomes in these areas for coverage decisions.

While our promising research began with breast cancer, the MMBM app is designed to address fundamental changes in brain circuitry impacting quality of life domains across many cancer types. This highlights the transformative potential of digital therapeutics and software-enhanced drug™ treatments to directly address the debilitating neurological and psychological symptoms that patients too often face alone.

At Click, we envision a future where, as part of this precision medicine approach, patients are also prescribed personalized software as medicine, available to them through their smartphone, which can address these often overlooked symptoms in cancer care. As part of this future, interventions like MMBM will be integrated into a multimodal digital treatment, leveraging cognitive, behavioral and drug-enhancing mechanisms of action to improve patient outcomes from multiple different angles. These interventions can be further customized and combined with specific medications for delivery as Software-Enhanced Drug™ treatments, working hand-in-hand with cancer treatments to improve patient outcomes and deliver a more personalized patient experience, ensuring patients feel supported throughout their care journey.